Wells Fargo & Company Aadi Bioscience, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 3,022 shares of AADI stock, worth $5,923. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,022

Previous 9,791 69.13%

Holding current value

$5,923

Previous $22,000 81.82%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.46 - $2.31 $9,882 - $15,636	-6,769 Reduced 69.13%	3,022 $4,000
Q1 2024 May 10, 2024	BUY	$1.59 - $2.44 $1,171 - $1,798	737 Added 8.14%	9,791 $22,000
Q4 2023 Feb 09, 2024	BUY	$1.97 - $5.41 $1,424 - $3,911	723 Added 8.68%	9,054 $18,000
Q3 2023 Nov 13, 2023	SELL	$4.84 - $7.13 $9,597 - $14,138	-1,983 Reduced 19.23%	8,331 $40,000
Q2 2023 Aug 15, 2023	BUY	$6.84 - $8.56 $38,249 - $47,867	5,592 Added 118.42%	10,314 $70,000
Q1 2023 May 12, 2023	BUY	$6.85 - $13.0 $21,618 - $41,028	3,156 Added 201.53%	4,722 $34,000
Q4 2022 Feb 13, 2023	SELL	$11.99 - $14.5 $1,894 - $2,291	-158 Reduced 9.16%	1,566 $20,000
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $4,390 - $5,190	-365 Reduced 17.47%	1,724 $25,000
Q2 2022 Aug 12, 2022	BUY	$11.57 - $17.92 $11,535 - $17,866	997 Added 91.3%	2,089 $26,000
Q1 2022 May 16, 2022	BUY	$16.65 - $24.97 $4,961 - $7,441	298 Added 37.53%	1,092 $18,000
Q4 2021 Feb 14, 2022	BUY	$19.32 - $29.02 $13,794 - $20,720	714 Added 892.5%	794 $19,000
Q3 2021 Nov 15, 2021	BUY	$25.52 - $41.85 $2,041 - $3,348	80 New	80 $2,000

Others Institutions Holding AADI

# of Institutions

Shares Held

12M

Call Options Held

9.4K

Put Options Held

2.5K

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $41.2M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Aadi Bioscience, Inc. Transaction History